Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ETON
- Price
- 17.15
- Stock movement up
- +0.08 (0.47%)
- Company name
- Eton Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 459.92M
- Ent value
- 504.18M
- Price/Sales
- 6.54
- Price/Book
- 19.89
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- 16.98
- PEG
- -
- EPS growth
- -32.22%
- 1 year return (CAGR)
- 2.02%
- 3 year return (CAGR)
- 69.05%
- 5 year return (CAGR)
- 11.66%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ETON does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | 21.58 |
| Price to FCF | 21.89 |
| Price to EBITDA | 347.63 |
| EV to EBITDA | 381.09 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 6.54 |
| Price to Book | 19.89 |
| EV to Sales | 7.17 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 26.82M |
| EPS (TTM) | -0.25 |
| FCF per share (TTM) | 0.78 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 70.32M |
| Gross profit (TTM) | 36.12M |
| Operating income (TTM) | -2.68M |
| Net income (TTM) | -6.68M |
| EPS (TTM) | -0.25 |
| EPS (1y forward) | 1.01 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 51.36% |
| Operating margin (TTM) | -3.81% |
| Profit margin (TTM) | -9.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 37.12M |
| Net receivables | 13.08M |
| Total current assets | 72.00M |
| Goodwill | 0.00 |
| Intangible assets | 31.88M |
| Property, plant and equipment | 613.00K |
| Total assets | 104.51M |
| Accounts payable | 14.26M |
| Short/Current long term debt | 3.26M |
| Total current liabilities | 44.18M |
| Total liabilities | 81.38M |
| Shareholder's equity | 23.13M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 21.31M |
| Capital expenditures (TTM) | 296.00K |
| Free cash flow (TTM) | 21.01M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -28.89% |
| Return on Assets | -6.39% |
| Return on Invested Capital | -12.49% |
| Cash Return on Invested Capital | 39.28% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 17.27 |
| Daily high | 17.52 |
| Daily low | 16.79 |
| Daily Volume | 257K |
| All-time high | 22.48 |
| 1y analyst estimate | 30.00 |
| Beta | 1.22 |
| EPS (TTM) | -0.25 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ETON | S&P500 | |
| Current price drop from All-time high | -23.71% | -1.82% |
| Highest price drop | -79.94% | -56.47% |
| Date of highest drop | 20 Oct 2022 | 9 Mar 2009 |
| Avg drop from high | -38.78% | -10.84% |
| Avg time to new high | 36 days | 12 days |
| Max time to new high | 942 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
459.92M
Marketcap category
Small-cap
Description
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-400 for treating adrenal insufficiency; ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Employees
31
Website
Investor relations
-
SEC filings
CEO
Sean Brynjelsen
Country
USA
City
Deer Park
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page